AKAN
Price
$4.01Alerts
Change
+$1.96 (+95.61%)
Updated
Nov 18, 04:59 PM (EDT)
Capitalization
454.36K
Intraday BUY SELL Signals
SCYX
Price
$2.86Alerts
Change
+$0.01 (+0.35%)
Updated
Nov 18, 04:59 PM (EDT)
Capitalization
34.82M
133 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AKAN vs SCYX

AKAN vs SCYX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AKAN vs. SCYX commentary
Nov 19, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKAN is a Buy and SCYX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AKAN with price predictions
Nov 17, 2026

AKAN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for AKAN turned positive on October 21, 2026. Looking at past instances where AKAN's MACD turned positive, the stock continued to rise in 37 of 38 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on AKAN as a result. In 66 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

AKAN moved above its 50-day moving average on November 16, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +229.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKAN advanced for three days, in 140 of 170 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKAN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

AKAN broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AKAN entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.138) is normal, around the industry mean (6.379). P/E Ratio (0.001) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.032) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. AKAN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKAN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
a Summary for SCYX with price predictions
Nov 17, 2026

SCYX in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 16, 2026

SCYX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 37 cases where SCYX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where SCYX advanced for three days, in 190 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SCYX as a result. In 69 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for SCYX turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 32 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCYX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for SCYX entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.520) is normal, around the industry mean (6.379). P/E Ratio (-3.846) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.647) is also within normal values, averaging (183.387).

The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. SCYX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCYX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

FUNDAMENTALS RATINGS
SCYX: Fundamental Ratings
SCYX
OUTLOOK RATING
1..100
4
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
83
P/E GROWTH RATING
1..100
33
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AKANSCYX
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 16 days ago
83%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
COMPARISON
Comparison
Nov 19, 2026
Stock price -- (AKAN: $2.05 vs. SCYX: $2.85)
Brand notoriety: AKAN and SCYX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AKAN: 160% vs. SCYX: 65%
Market capitalization -- AKAN: $454.36K vs. SCYX: $34.82M
AKAN [@Pharmaceuticals: Generic] is valued at $454.36K. SCYX’s [@Pharmaceuticals: Generic] market capitalization is $34.82M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKAN’s FA Score shows that 1 FA rating(s) are green while SCYX’s FA Score has 2 green FA rating(s).

  • AKAN’s FA Score: 1 green, 4 red.
  • SCYX’s FA Score: 2 green, 3 red.
According to our system of comparison, SCYX is a better buy in the long-term than AKAN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKAN’s TA Score shows that 4 TA indicator(s) are bullish while SCYX’s TA Score has 4 bullish TA indicator(s).

  • AKAN’s TA Score: 4 bullish, 5 bearish.
  • SCYX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SCYX is a better buy in the short-term than AKAN.

Price Growth

AKAN (@Pharmaceuticals: Generic) experienced а +177.74% price change this week, while SCYX (@Pharmaceuticals: Generic) price change was -19.03% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.75%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -8.43%.

Reported Earning Dates

SCYX is expected to report earnings on Mar 31, 2027.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.75% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
Interact to see
Advertisement

AKAN and

Correlation & Price change

A.I.dvisor tells us that AKAN and CGC have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AKAN and CGC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKAN
1D Price
Change %
AKAN100%
-7.24%
CGC - AKAN
27%
Poorly correlated
-2.67%
SNOA - AKAN
25%
Poorly correlated
-4.56%
OGI - AKAN
24%
Poorly correlated
-2.27%
SNDL - AKAN
24%
Poorly correlated
N/A
SCYX - AKAN
22%
Poorly correlated
-1.72%
More

SCYX and

Correlation & Price change

A.I.dvisor tells us that SCYX and ACET have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCYX and ACET's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCYX
1D Price
Change %
SCYX100%
-1.72%
ACET - SCYX
27%
Poorly correlated
+1.09%
CRDL - SCYX
26%
Poorly correlated
-0.82%
ELAN - SCYX
26%
Poorly correlated
-2.12%
DERM - SCYX
25%
Poorly correlated
+5.41%
AKBA - SCYX
24%
Poorly correlated
-10.74%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HRMY33.010.05
+0.15%
Harmony Biosciences Holdings
IMCC0.49N/A
-0.26%
IM Cannabis Corp
GMED69.99-0.51
-0.72%
Globus Medical
TECX20.08-0.90
-4.29%
Tectonic Therapeutic Inc.
CRBP3.01-0.37
-10.81%
Corbus Pharmaceuticals Holdings